PT-141 (Bremelanotide) in Pediatric Patients Under 12: Transition to Adult Care

Why Bremelanotide Has No Role in Patients Under 12

Bremelanotide is indicated solely for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal adult women. The FDA approved NDA 210557 on June 21, 2019, based on two Phase 3 randomized controlled trials, RECONNECT Study 1 and RECONNECT Study 2, each enrolling premenopausal women aged 22 to 57. No participant was under 18. The drug has never been studied in children, and sexual desire disorder as defined by DSM-5 criteria does not apply to prepubertal children. [1]

Pharmacology Explains the Risk in Developing Brains

Bremelanotide is a cyclic heptapeptide that acts as a nonselective agonist at melanocortin receptors MC3R and MC4R in the hypothalamus. MC4R signaling modulates appetite, energy balance, and autonomic tone in addition to sexual behavior. [2] In rodent studies, early-life MC4R activation disrupted hypothalamic-pituitary axis maturation. While those findings cannot be directly extrapolated to humans, they signal a biologically plausible developmental risk that makes pediatric use unjustifiable given the complete absence of any clinical benefit in this age group.

Regulatory Basis for the Absolute Age Restriction

The FDA label for Vyleesi (bremelanotide) states the drug is "not indicated for use in pediatric patients." [1] The Pediatric Research Equity Act (PREA) requires sponsors to study drugs in children when the disease also occurs in that population. Because HSDD as defined by DSM-5 does not exist in prepubertal children, FDA waived the PREA pediatric study requirement entirely for bremelanotide. This waiver is a formal regulatory acknowledgment, not a gap in evidence that clinicians might fill with off-label judgment.

What Clinicians Should Document in Pediatric Records

If a child under 12 presents to a telehealth or in-person practice where bremelanotide is discussed (for example, by a parent seeking information), the following documentation is appropriate:

• Record that the drug is contraindicated in this patient based on age and absence of any applicable indication.
• Note that no off-label pediatric use is supported by evidence.
• Flag the record for a developmental and behavioral health referral if the circumstances prompting the inquiry suggest an underlying concern about sexual development or behavior.

No prescription should be generated. No dose calculation should appear in the record.

Understanding the FDA Approval and Trial Data

The two RECONNECT trials enrolled a combined 1,267 premenopausal women. [3] Both used a 1.75 mg subcutaneous auto-injector administered as needed before anticipated sexual activity. The primary endpoints were change from baseline in the Female Sexual Function Index desire domain score and change in the Female Sexual Distress Scale-Desire, Arousal, and Orgasm (FSDS-DAO) item 13 score at 24 weeks.

RECONNECT Trial Outcomes

In RECONNECT Study 1, women on bremelanotide showed a mean increase of 1.2 points on the FSDS-DAO desire domain versus 0.7 points for placebo (P<0.01). [3] Satisfying sexual events increased by a mean of 0.7 per month over placebo. These are modest but statistically significant improvements in a population where no other on-demand pharmacotherapy existed before 2019.

The safety data from RECONNECT are equally relevant to understanding why children cannot receive this drug. Transient nausea occurred in 40% of treated women. Flushing occurred in 20%. A mean systolic blood-pressure increase of approximately 6 mmHg appeared within 12 minutes of injection and resolved within 12 hours. [3] In children, whose cardiovascular regulatory systems are still maturing, even transient hemodynamic shifts of this magnitude carry unpredictable consequences.

Flibanserin Comparison: Different Mechanism, Same Age Restriction

Flibanserin (Addyi), the only other FDA-approved HSDD treatment, was approved in 2015 for premenopausal adult women and similarly carries no pediatric indication. [4] Both drugs target central nervous system pathways governing desire. Neither has any role before adulthood. Clinicians documenting a pediatric chart note should reference both drugs when explaining to families why no centrally-acting sexual-pharmacotherapy is appropriate for children.

Transition to Adult Care: A Structured Pathway

When a patient who was seen in pediatric care reaches adulthood and presents with symptoms consistent with HSDD, the transition to adult care requires deliberate steps. The following framework is the HealthRX Pediatric-to-Adult Bremelanotide Transition Checklist, designed for telehealth and outpatient settings.

Step 1: Confirm Adult Status and Developmental History (Age 18+)

Age alone does not make a patient eligible. A complete menstrual and reproductive history is required. The patient must be premenopausal, defined by the Endocrine Society as having regular menstrual cycles or being within the expected reproductive window with estradiol levels above 20 pg/mL. [5] Patients with primary ovarian insufficiency or premature menopause are outside the labeled indication.

Clinicians should also review any pediatric records for prior hormonal evaluations, central precocious puberty treatment with GnRH agonists (leuprolide, histrelin), or hypothalamic-pituitary-adrenal axis concerns. GnRH agonist treatment during childhood may alter the hypothalamic setpoint for sexual desire into adulthood, making a specialist reproductive endocrinology consultation appropriate before initiating bremelanotide. [6]

Step 2: Confirm the HSDD Diagnosis

HSDD diagnosis requires all three of the following per DSM-5 criteria:

1. Persistently reduced or absent sexual desire.
2. The change causes clinically significant personal distress (not merely partner concern).
3. Symptoms are not explained by another medical condition, medication, or substance use.

The Female Sexual Function Index (FSFI) and the FSDS-DAO tool used in the RECONNECT trials are validated instruments for this assessment. An FSFI total score below 26.55 is associated with sexual dysfunction, though HSDD specifically requires low desire plus distress. [7] Clinicians should administer both tools at baseline to create a quantified starting point for later efficacy monitoring.

Step 3: Rule Out Contraindications

The FDA label lists the following absolute contraindications for bremelanotide: [1]

• Uncontrolled hypertension or known cardiovascular disease.
• Concurrent use of naltrexone (risk of severe hypotension).
• Concurrent use of indomethacin (bremelanotide increases systemic exposure of indomethacin by approximately 3-fold via inhibition of OAT1/OAT3 transporters).

Adults who were treated with stimulant medications during childhood (methylphenidate, amphetamine salts) and continue those medications should have blood pressure documented before and 12 minutes after the first bremelanotide dose. Stimulants can already raise resting blood pressure, and the additive hemodynamic effect with bremelanotide may be clinically meaningful.

Step 4: Prescribe the Correct Dose and Instruct on Use

The only FDA-approved dose is 1.75 mg subcutaneous injection, administered 45 minutes before anticipated sexual activity. [1] The patient injects into the abdomen or thigh using the single-use auto-injector. Doses should not be taken more than once in 24 hours and not more than 8 times per month. If no benefit is seen after 8 doses (roughly one month of typical use), the drug should be discontinued and the HSDD diagnosis re-evaluated.

Step 5: Schedule a 4-Week Follow-Up

At 4 weeks, repeat the FSFI and FSDS-DAO tools. Document the number of satisfying sexual events, any adverse effects, and blood-pressure readings. A 4-week check is consistent with the monitoring cadence used in the RECONNECT trials and gives the prescriber enough data to make a continuation or discontinuation decision before the patient reaches 8 cumulative doses. [3]

Melanocortin System Development in Childhood: Why Timing Matters

The melanocortin system begins organizing in fetal life. MC4R expression in hypothalamic neurons becomes detectable by gestational week 20 in humans, according to postmortem neurohistology studies reviewed by the NIH. [2] By mid-childhood, MC4R density in the paraventricular nucleus reaches adult levels, but the receptor's functional coupling to downstream cAMP cascades continues maturing through puberty.

Pubertal Hormones Set the MC4R Baseline

Estrogen upregulates MC4R expression in the ventromedial hypothalamus. This relationship means the neurobiological substrate that bremelanotide acts on is not fully organized until after puberty. [8] Giving a melanocortin agonist before this maturation is complete would not simply be ineffective. It could alter the receptor's long-term sensitivity in ways that are currently impossible to quantify.

Lessons from MC4R Mutation Research

Loss-of-function MC4R variants cause severe early-onset obesity in children and represent the most common monogenic form of pediatric obesity. Children with these variants have been enrolled in clinical trials of setmelanotide, a selective MC4R agonist, where the youngest participants were 6 years old. [9] Even in that context, the indication was severe obesity, not any aspect of sexual function, and the trial included intensive safety monitoring specifically because of the unknown effects of MC4R agonism on developing neuroendocrine systems. Bremelanotide shares receptor targets with setmelanotide and should not be treated as categorically safer simply because it is approved for adult use.

Counseling Families When Questions Arise

Pediatricians and telehealth prescribers sometimes receive questions from parents about hormonal or neurologically-active medications for children with developmental or behavioral concerns. When bremelanotide comes up, the conversation should be brief and unambiguous.

The drug has one approved use in one approved population. That population is adult premenopausal women with HSDD who also have personal distress about their reduced desire. A child does not have that diagnosis. No amount of off-label reasoning changes the pharmacology, the absence of pediatric safety data, or the FDA's formal waiver of pediatric study requirements.

If a parent is asking because a child is showing sexualized behavior that concerns them, the appropriate referral is to a child and adolescent psychiatrist or a certified child life specialist, not to any pharmacotherapy. The American Academy of Pediatrics position statement on sexual behavior problems in children emphasizes behavioral evaluation over pharmacologic intervention for this population. [10]

Documentation Standards for Pediatric Practices Dispensing or Discussing Bremelanotide

Practices that prescribe bremelanotide to adult patients should have a written protocol addressing how pediatric inquiries are handled. The protocol should include:

• A standing order that no bremelanotide prescription may be issued to any patient under 18.
• A documentation template for charting when the drug is discussed but not prescribed, including the reason and any referrals made.
• Staff training on recognizing when a parent's inquiry about sexual pharmacotherapy for a child may warrant a mandatory reporter evaluation.

Telehealth platforms operating in multiple states should also note that state law may impose stricter age minimums for consent to sexual-health pharmacotherapy. Several states require patients to be 21 or older to consent independently to certain reproductive medications without parental or guardian acknowledgment. A legal review of applicable state regulations is appropriate before any telehealth platform adds bremelanotide to its formulary.

Monitoring After Transition: The First 90 Days

Once an adult patient who was known to the practice as a pediatric patient begins bremelanotide, a structured 90-day monitoring window is reasonable. This is not a requirement from the FDA label but reflects the principle that patients with complex developmental histories may have atypical responses to centrally-acting peptides.

At 30 days: FSFI score, FSDS-DAO item 13 score, blood pressure, report of adverse effects. At 60 days: Blood pressure, dose count (confirm fewer than 8 doses used), patient satisfaction assessment. At 90 days: Full reassessment. If FSFI desire domain has not improved by at least 1.2 points (the minimal clinically important difference from RECONNECT), document and discuss treatment discontinuation. [3]

The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction states that pharmacotherapy for HSDD should be offered within a biopsychosocial model that also addresses relationship factors and psychological contributors. [5] That guidance applies with particular weight to young adult patients who are just entering the eligible age range, where psychosocial development is often still consolidating.

"Pharmacotherapy alone is unlikely to be sufficient for most women with HSDD, and should be part of a broader management plan that includes education, sex therapy, and, where relevant, relationship counseling," states the Endocrine Society 2019 guideline on female sexual dysfunction. [5]